Hyperglycemia - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Hyperglycemia - Pipeline Review, H1 2016

Hyperglycemia - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Hyperglycemia - Pipeline Review, H1 2016
Published Jun 08, 2016
44 pages — Published Jun 08, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Hyperglycemia - Pipeline Review, H1 2016, provides an overview of the Hyperglycemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hyperglycemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hyperglycemia and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hyperglycemia
- The report reviews pipeline therapeutics for Hyperglycemia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Hyperglycemia therapeutics and enlists all their major and minor projects
- The report assesses Hyperglycemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Hyperglycemia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Hyperglycemia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hyperglycemia pipeline depth and focus of Indication therapeutics
- Develop and design in

  
Source:
Document ID
GMDHC8203IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
Introduction51
  Global Markets Direct Report Coverage51
Hyperglycemia Overview61
Therapeutics Development72
  Pipeline Products for Hyperglycemia Overview71
  Pipeline Products for Hyperglycemia Comparative Analysis81
Hyperglycemia Therapeutics under Development by Companies91
Hyperglycemia Therapeutics under Investigation by Universities/Institutes101
Hyperglycemia Pipeline Products Glance112
  Clinical Stage Products111
  Early Stage Products121
Hyperglycemia Products under Development by Companies131
Hyperglycemia Products under Investigation by Universities/Institutes141
Hyperglycemia Companies Involved in Therapeutics Development153
  Kissei Pharmaceutical Co., Ltd.151
  Mitsubishi Tanabe Pharma Corporation161
  PhaseBio Pharmaceuticals, Inc.171
Hyperglycemia Therapeutics Assessment189
  Assessment by Monotherapy Products181
  Assessment by Target192
  Assessment by Mechanism of Action212
  Assessment by Route of Administration232
  Assessment by Molecule Type252
Drug Profiles2713
  CDR-267F018 - Drug Profile271
    Product Description271
    Mechanism of Action271
    R&D Progress271
  Drugs to Inhibit ABHD6 for Gastrointestinal and Metabolic Disorders - Drug Profile281
    Product Description281
    Mechanism of Action281
    R&D Progress281
  FGH-10019 - Drug Profile291
    Product Description291
    Mechanism of Action291
    R&D Progress291
  KR-62980 - Drug Profile301
    Product Description301
    Mechanism of Action301
    R&D Progress302
  PE-0139 - Drug Profile321
    Product Description321
    Mechanism of Action321
    R&D Progress322
  Peptides to Antagonize Glucagon Receptor for Type 2 Diabetes and Hyperglycemia - Drug Profile341
    Product Description341
    Mechanism of Action341
    R&D Progress341
  Small Molecule to Inhibit SGLT1 for Postprandial Hyperglycemia - Drug Profile351
    Product Description351
    Mechanism of Action351
    R&D Progress351
  Small Molecules to Antagonize PST Receptor for Dysglycemic States - Drug Profile361
    Product Description361
    Mechanism of Action361
    R&D Progress361
  Small Molecules to Inhibit DPP-IV for Hyperglycemia - Drug Profile371
    Product Description371
    Mechanism of Action371
    R&D Progress371
  Small Molecules to Inhibit PEPCK for Type 2 Diabetes and Hyperglycemia - Drug Profile381
    Product Description381
    Mechanism of Action381
    R&D Progress381
  Small Molecules to Inhibit Prokineticin Receptor for Metabolic Disorders - Drug Profile391
    Product Description391
    Mechanism of Action391
    R&D Progress391
Hyperglycemia Recent Pipeline Updates402
Hyperglycemia - Dormant Projects421
Appendix432
  Methodology431
  Coverage431
  Secondary Research431
  Primary Research431
  Expert Panel Validation431
  Contact Us431
  Disclaimer441

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Hyperglycemia - Pipeline Review, H1 2016" Jun 08, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Hyperglycemia-Pipeline-Review-H1-2016-2088-15924>
  
APA:
Global Markets Direct - Market Research. (2016). Hyperglycemia - Pipeline Review, H1 2016 Jun 08, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Hyperglycemia-Pipeline-Review-H1-2016-2088-15924>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.